Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The FDA signed off Flexion Therapeutics Inc's (NASDAQ: FLXN) Phase 1b proof of concept trial evaluating FX301 administered as a popliteal fossa block (a commonly used nerve block in the foot and ankle-related surgeries) in patients undergoing bunionectomy.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- FX301 combines NaV1.7 inhibitor (funapide) with thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block.
- The study will start in the first half of this year, with topline data expected in late 2021.
- The company says that FX301 can potentially provide non-opioid pain relief for at least 3 to 5 days while preserving motor function following musculoskeletal surgery.
- Preclinical data demonstrated analgesic effect beginning at 1-hour post-dosing compared to placebo and significantly more significant analgesic effect than liposomal bupivacaine at 36 hours post-dosing.
- Price Action: FLXN shares are 1.4% higher at $11.25 in market trading hours on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.